Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Charlie A. Elliot"'
Autor:
Yousef Shahin, Samer Alabed, Syed Rehan Quadery, Robert A. Lewis, Christopher Johns, Dheyaa Alkhanfar, Maria Sukhanenko, Faisal Alandejani, Pankaj Garg, Charlie A. Elliot, Abdul Hameed, Athaniosis Charalampopoulos, James M. Wild, Robin Condliffe, Andrew J. Swift, David G. Kiely
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Providing prognostic information is important when counseling patients and planning treatment strategies in chronic thromboembolic pulmonary hypertension (CTEPH). The aim of this study was to assess the prognostic value of gold standard imaging of ca
Externí odkaz:
https://doaj.org/article/0b2b2cc5f78645a7aa3f4ef68cab0546
Autor:
Faisal Alandejani, Abdul Hameed, Euan Tubman, Samer Alabed, Yousef Shahin, Robert A. Lewis, Krit Dwivedi, Aqeeb Mahmood, Jennifer Middleton, Lisa Watson, Dheyaa Alkhanfar, Christopher S. Johns, Smitha Rajaram, Pankaj Garg, Robin Condliffe, Charlie A. Elliot, A. A. Roger Thompson, Alexander M. K. Rothman, Athanasios Charalampopoulos, Allan Lawrie, Jim M. Wild, Andrew J. Swift, David G. Kiely
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
BackgroundCurrent European Society of Cardiology and European Respiratory Society guidelines recommend regular risk stratification with an aim of treating patients with pulmonary arterial hypertension (PAH) to improve or maintain low-risk status (
Externí odkaz:
https://doaj.org/article/ad9c45345a914ca4aefc57d3947939a4
Autor:
Laura C. Saunders, Chris S. Johns, Neil J. Stewart, Charlotte J. E. Oram, David A. Capener, Valentina O. Puntmann, Charlie A. Elliot, Robin C. Condliffe, David G. Kiely, Martin J. Graves, Jim M. Wild, Andy J. Swift
Publikováno v:
Journal of Cardiovascular Magnetic Resonance, Vol 20, Iss 1, Pp 1-11 (2018)
Abstract Background Native T1 may be a sensitive, contrast-free, non-invasive cardiovascular magnetic resonance (CMR) marker of myocardial tissue changes in patients with pulmonary artery hypertension. However, the diagnostic and prognostic value of
Externí odkaz:
https://doaj.org/article/1553f1d71a0f44ba852ee09d966f87a1
Autor:
Kris Bauchmuller, Robin Condliffe, Jennifer Southern, Catherine Billings, Athanasios Charalampopoulos, Charlie A. Elliot, Abdul Hameed, David G. Kiely, Ian Sabroe, A.A. Roger Thompson, Ajay Raithatha, Gary H. Mills
Publikováno v:
ERJ Open Research, Vol 7, Iss 2 (2021)
Pulmonary hypertension (PH) is a life-shortening condition characterised by episodes of decompensation precipitated by factors such as disease progression, arrhythmias and sepsis. Surgery and pregnancy also place additional strain on the right ventri
Externí odkaz:
https://doaj.org/article/c41ee9e56e4c402780f1b82b91f1a2f0
Autor:
Andrew J. Peacock, Yi Ling, Martin K. Johnson, David G. Kiely, Robin Condliffe, Charlie A. Elliot, J. Simon R. Gibbs, Luke S. Howard, Joanna Pepke-Zaba, Karen K.K. Sheares, Paul A. Corris, Andrew J. Fisher, James L. Lordan, Sean Gaine, J. Gerry Coghlan, S. John Wort, Michael A. Gatzoulis
Publikováno v:
Pulmonary Circulation, Vol 10 (2020)
Patients classified as idiopathic pulmonary arterial hypertension (defined as Group 1 on European Respiratory Society (ERS)/European Cardiac Society (ESC) criteria) may have evidence of minor co-existing lung disease on thoracic computed tomography.
Externí odkaz:
https://doaj.org/article/706f765a1ce94cf38464ec652442ad0a
Autor:
Catherine G. Billings, Robert Lewis, Judith A. Hurdman, Robin Condliffe, Charlie A. Elliot, A.A. Roger Thompson, Ian A. Smith, Matthew Austin, Iain J. Armstrong, Neil Hamilton, Athanasios Charalampopoulos, Ian Sabroe, Andrew J. Swift, Alexander M. Rothman, Jim M. Wild, Allan Lawrie, Judith C. Waterhouse, David G. Kiely
Publikováno v:
Pulmonary Circulation, Vol 9 (2019)
Pulmonary hypertension (PH) is classified into five groups based on disease etiology but there is only limited information on the prognostic value of exercise testing in non-group 1 PH. In group 1 PH, the incremental shuttle walking test (ISWT) dista
Externí odkaz:
https://doaj.org/article/5818b993517d4ff5a41fb5090e781b80
Autor:
Catherine G. Billings, Robert Lewis, Iain J. Armstrong, Judith A. Hurdman, Ian A. Smith, Matthew Austin, Charlie A. Elliot, Athanasios Charalampopoulos, Ian Sabroe, Allan Lawrie, A. A. Roger Thompson, Robin Condliffe, David G. Kiely
Publikováno v:
Frontiers in Medicine, Vol 5 (2018)
Background: There is increasing interest in screening for and diagnosing pulmonary hypertension earlier in the course of disease. However, there is limited data on cardiopulmonary abnormalities in patients with pulmonary hypertension newly diagnosed
Externí odkaz:
https://doaj.org/article/5d7341f9766a46659b3854008f600040
Autor:
Robin Condliffe, Charlie A. Elliot, Judith Hurdman, Ian Sabroe, Catherine Billings, David G. Kiely, Neil Hamilton
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 8 (2014)
Introduction: Ambrisentan is an oral selective endothelin receptor antagonist licensed for use in pulmonary arterial hypertension (PAH). There are few data on clinical use and long-term tolerability in a wider range of patients with pulmonary hyperte
Externí odkaz:
https://doaj.org/article/e2f4d57975764781989545c580ef6e5b
Autor:
Marius M Hoeper, Krit Dwivedi, Christine Pausch, Robert A Lewis, Karen M Olsson, Doerte Huscher, David Pittrow, Ekkehard Grünig, Gerd Staehler, Carmine Dario Vizza, Henning Gall, Oliver Distler, Christian Opitz, John Simon R Gibbs, Marion Delcroix, Da-Hee Park, Hossein Ardeschir Ghofrani, Ralf Ewert, Harald Kaemmerer, Hans-Joachim Kabitz, Dirk Skowasch, Juergen Behr, Katrin Milger, Tobias J Lange, Heinrike Wilkens, Hans-Jürgen Seyfarth, Matthias Held, Daniel Dumitrescu, Iraklis Tsangaris, Anton Vonk-Noordegraaf, Silvia Ulrich, Hans Klose, Martin Claussen, Stephan Eisenmann, Kai-Helge Schmidt, Andrew J Swift, Alfred A Roger Thompson, Charlie A Elliot, Stephan Rosenkranz, Robin Condliffe, David G Kiely, Michael Halank
Publikováno v:
The Lancet. Respiratory medicine. 10(10)
BACKGROUND: Among patients meeting diagnostic criteria for idiopathic pulmonary arterial hypertension (IPAH), there is an emerging lung phenotype characterised by a low diffusion capacity for carbon monoxide (DLCO) and a smoking history. The present
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10785360eb41761ee773f8bbc41af06b
https://pubmed.ncbi.nlm.nih.gov/36191599
https://pubmed.ncbi.nlm.nih.gov/36191599
Autor:
Sheila, Ramjug, Nehal, Hussain, Judith, Hurdman, Catherine, Billings, Athanasios, Charalampopoulos, Charlie A, Elliot, David G, Kiely, Ian, Sabroe, Smitha, Rajaram, Andrew J, Swift, Robin, Condliffe
Publikováno v:
Chest. 152(1)
Previous studies have identified survival in systemic sclerosis (SSc)-associated pulmonary arterial hypertension (SSc-PAH) as being worse than in idiopathic pulmonary arterial hypertension (IPAH). We investigated differences between these conditions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::85135b5f440f042f04c2c567d89de7e6
https://pubmed.ncbi.nlm.nih.gov/28223154
https://pubmed.ncbi.nlm.nih.gov/28223154